Don't fall for the 'next best action' trap

OKRA 15 September, 2020. London, UK.
OKRA has announced a new, free webinar called 'Why Next Best Action is not enough', a panel will discuss the urgent need to move beyond the current trend of adding simplistic or 'dumb' AI tools to sales force dashboards.

These AI tools make sense for managers - they are very easy to apply, inexpensive, and give reps an enhanced view of the market - but in the medium-to-long term will likely cause more harm than good.

During the webinar we will discuss why we must immediately take more care when installing these systems. In particular, we must avoid three common traits:

Autocratic

Most of us would recoil in fear if we were told that our next manager was going to be an autocrat. We would far rather a boss who used carrots rather than sticks to motivate his/her workforce. We would value empathy and flexibility in our leadership: ultimately it's preferable to have someone we want to work for.

Yet the next best action systems are very much the opposite. They bark out single-line instructions that come with very little nuance. Even if they are right, it won't take long for us to want to 'rage against the machine'.

Unexplained

The vast majority of AI systems being deployed are 'black box'. And there's a very good reason for that: AI systems learn as they go, and it eventually becomes more and more difficult to understand their reasoning. In fact, the more sophisticated and intelligent the AI, the harder it is to explain the decisions it makes.

But like the autocratic manager, we quickly lose trust and respect if we cannot break down our actions or decisions into rational arguments.

Dumb

There are different grades of AI. Many of the systems being deployed currently are 'rules-based systems' - where an inferior artificial intelligence is given guidelines and parameters to work with, in order that it can figure out what it needs to.

And you would think that by setting up such a scenario, you would be helping the AI, a little bit like adding stabilisers onto a child’s bicycle to stop them falling over.

However it is also easy to understand that nobody would ever compete in the Tour de France with stabilisers on their bike. These stabilisers would stop you ever from becoming an elite cyclist, and rules-based systems are similarly unable to become as smart as we require.

Non-rules based systems, or 'deep' AI, are far more difficult to create. Typically, such systems are not even told the rules of the game when they start playing. However they quickly supersede their counterparts and become insightful - and useful.

Ultimately, it’s about trust

Our industry has experienced countless 'digital transformation' initiatives that have failed to get off the ground. Often that's not because of the sophistication of the technology but because of the lack of belief or trust in the system. Next best action systems are no different in this regard.

Join this free webinar to witness the solution - what is possible - and how to avoid these common pitfalls that could otherwise result in a lot of wasted money, morale and a lack of interest in engaging with future solutions.

For durther information and to register, please visit:
https://okra.ai/webinar

About OKRA

At OKRA we are fostering a new generation of ArtificiaI Intelligence (AI) solutions that support the healthcare ecosystem. Our solutions are implemented by top pharma companies throughout the product pipeline to empower employees in decision making around complex problems.

OKRA's AI solutions are translating large clinical, scientific and commercial data sets into actionable insights that employees in life science companies can easily query at their desks or whilst on the move.

We believe that for AI to truly empower people, the insights presented must be explainable and instil confidence when driving action. Our suite of products have been built in partnership with top life science companies, with a focus on empowering the people to take action.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...